Practical Recommendations in Immuno and Molecular Oncology (PRIMO)
February 5-8, 2025
Honolulu, HI
DISCLOSURE INDEXThe Medical Educator Consortium, Inc. in accordance with the Joint Accreditation Criteria and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, has implemented a process where everyone who is in a position to control the content of a CME/CE activity has disclosed to us all financial relationships with any ineligible company that they have had over the past 24 months. There is no minimum financial threshold, disclosure must be made regardless of whether the person views the financial relationships
as relevant to the education. The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners.
As a Joint Accreditation (JA) Provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All individuals who are in a position to control the content of this educational activity have disclosed all financial relationships with any ineligible companiesto the provider. This disclosure includes all persons in control of content to include staff and educational committee members involved in the planning process.
The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.
Speakers/Moderators – Reported Relevant Financial Disclosure(s)
Jared D. Acoba, MD
Grant/Research Support: GSK
Sanjiv S. Agarwala, MD, FASCO
Has no relevant financial relationships
Daniel H. Ahn, DO, MS
Grant/Research Support: AstraZeneca
Consultant: Bayer
Stock Shareholders: Natera
Shannon Baxter, PhD
Has no relevant financial relationships
Susana Campos, MD, MPH
Consultant: Esai, GlaxoSmithKline, Merck, Pfizer, Immunogen
Michael E. Carney, MD, FACOG
Has no relevant financial relationships
Darlena Chadwick, MBA, MSN, FACHE
Has no relevant financial relationships
Cecilia Choi, MD
Has no relevant financial relationships
Amy L. Cummings, MD, PhD
Consultant: AstraZeneca, Bristol Myers Squibb, Oncohost, Tempus
Don S. Dizon, MD, FACP, FASCO
Grant/Research Support: Bristol Myers Squibb
Consultant: Puma,
Other: Data Safety Monitoring Board: Astra Zeneca, Data Safety Monitoring Board & Change
Management: Clovis
Stock Shareholders: Midi, Doximity
Jami Fukui, MD
Has no relevant financial relationships
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Grant/Research Support: BMS, Pharmacosmos
Nitin Jain, MD
Grant/Research Support: Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Kite/Gilead, Mingsight Pharmaceuticals, Takeda, Medisix, Loxo Oncology, Novalgen, Dialectic Therapeutics, Newave Pharmaceutical Inc., Novartis, Carna Biosciences, Sana Biotechnology, Kisoji Biotechnology
Consultant: Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, BMS, Adaptive Biotechnologies, Kite/Gilead, Precision Biosciences, Beigene, Cellectis, MEI Pharma, Ipsen, CareDX, MingSight Pharmaceuticals, Autolus, Novalgen
Robert Kim, MD
Has no relevant financial relationships
Kami J. Maddocks, MD
Consultant: Abbvie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, Genetech, Genmab, Incyte, Janssen, Kite, MorphoSys
Midhun Malla, MD, MS
Consultant: Exegesis, Ipsen, Natera
Tom Martin, MD
Grant/Research Support: Sanofi, Janssen, Amgen, BMS
Consultant: GSK, Roche/Pfizer
Shane Y. Morita, MD, MBA, PhD, FACS, FSSO
Has no relevant financial relationships
Misako Nagasaka, MD, PhD
Grant/Research Support: AstraZeneca, Daiichi Sankyo, Lilly, Janssen, BMS/Mirati, AnHeart/Nuvation, Nuvalent, JintsBIO, D3Bio, Boehringer Ingelheim, Merus
Consultant: Caris Life Sciences
Speakers’ Bureau: Janssen, Pfizer, Takeda, Blueprint Medicine
Stock Shareholders: MBrace Therapeutics
Jorge J. Nieva, MD
Grant/Research Support: Genentech, Merck
Consultant: Aadi Biosciences, Affyimmune, ANP Technologies, Astra Zeneca, BioAtla, G1 Therapeutics, Genentech, Kalivir Mindmed, Naveris, Sanofi
Stock Shareholders: Cansera, Epic Sciences, Indee Bio, Quantgene, Amgen, Johnson & Johnson, Novartis
Joyce O’Shaughnessy, MD
Has no relevant financial relationships
Alexander B. Olawaiye, MD
Has no relevant financial relationships
Chandler H. Park, MD, MSc, FACP
Grant/Research Support: AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Gilead Sciences, Janssen, Merck, Pfizer/Roche
Consultant: Aveo, AstraZeneca, Bristol-Myers Squibb, Caris, Exelixis, Eisai, Gilead Sciences, Janssen, Pfizer, Merck
Speakers’ Bureau: Eisai, Gilead Sciences, Pfizer, AstraZeneca, Merck, Janssen
Mark Pegram, MD
Consultant: Roche/Genentech, Stemline, AstraZeneca/Daiichi Sankyo
Luis E. Raez, MD, FACP, FASCO
Grant/Research Support: AstraZeneca, Pfizer, Velos, Merck, TG Therapeutics, BMS, Natera, Guardant Health, Genentech, Onc4, Anheart, Arcus Biosciences
Consultant: Bayer, AstraZeneca, Pfizer, Merck, Novartis
Merrick I. Ross, MD
Consultant: Merck – US Global Advisory Board Member
Hope S. Rugo, MD, FASCO
Grant/Research Support: AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, Ambryx
Consultant: Chugai, Puma, Sanofi, Napo, Mylan
Stuart Tsuji, MD, PhD
Has no relevant financial relationships
Naoto T. Ueno, MD, PhD, FACP
Grant/Research Support: AnHeart Therapeutics Inc., Eisai Co., Ltd., Gilead Sciences, Inc., Phoenix Molecular Designs, Daiichi Sankyo, Inc., Puma Biotechnology, Inc., Merck & Co., Oncolys BioPharma Inc., OBI Pharma Inc., ChemDiv, Inc., Tolero Pharmaceuticals, Inc., and VITRAC Therapeutics, LLC All have ended
Consultant: AstraZeneca Pharmaceuticals LP (USA and UK), Bayer AG (ended), Bristol Myers Squibb Company, Carna Biosciences, Inc., CytoDyn Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly, Genentech, Inc. (ended), Genomic Health, Inc. (ended), Gilead Sciences, Inc.(ended), Lavender Health (ended), OncoCyte Corporation (ended), Pear Bio, Peptilogics, Inc.(ended), Pfizer Inc.(ended), Phoenix Molecular Designs, Preferred Medicine (ended), Carisma Therapeutics Inc.(ended), Sysmex Corporation (ended), Takeda Pharmaceutical Company Limited (Japan)(ended), and Unitech Medical, Inc.(ended)
Speakers’ Bureau: AstraZeneca Pharmaceuticals LP (ended), Chugai Roche, Inc.(ended), Daiichi Sankyo
Co., Ltd.(ended), Kyowa Kirin Co., Ltd.(ended), Pfizer Inc.(ended), Eli Lilly (ended).
Stock Shareholders: Pear Bio, Phoenix Molecular Designs
Vicente Valero, MD, FACP
Consultant: Novartis, AstraZeneca, Roche
Julie M. Vose, MD, MBA
Grant/Research Support: GenMab/Abbvie, Ipsen, Loxo
Consultant: GenMab/Abbvie
Eunice S. Wang, MD
Consultant: Abbvie, CTI Biopharma, BMS, Blueprint, Daiichi Sankyo, Gilead, GSK, Immunogen, J&J, Kite,
Kura, Novartis, Qiagen, Rigel, Ryvu, Schrodinger, Servier, Sumitomo, Syndax, Takeda
Speakers’ Bureau: Astellas, Pfizer, Dava, Daiichi Sankyo
Other: Data Safety Monitoring Committee: Abbvie, Gilead
Yousef Zakharia, MD
Consultant: Advisory Board: BMS, EMD Serono, Exelixis, Eisai, Gilead, Janssen, Pfizer, Seagen
The Medical Educator Consortium, Inc. in accordance with the Joint Accreditation Criteria and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, has implemented a process where everyone who is in a position to control the content of a CME/CE activity has disclosed to us all financial relationships with any ineligible company that they have had over the past 24 months. There is no minimum financial threshold, disclosure must be made regardless of whether the person views the financial relationships as relevant to the education. The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners.
As a Joint Accreditation (JA) Provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All individuals who are in a position to control the content of this educational activity have disclosed all financial relationships with any ineligible companies to the provider. This disclosure includes all persons in control of content to include staff and educational committee members involved in the planning process.
The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.
Speakers/Moderators – Relevant Financial Disclosure(s)
Jared D. Acoba, MD
Grant/Research Support: GSK
Sanjiv S. Agarwala, MD, FASCO
Has no relevant financial relationships
Daniel H. Ahn, DO, MS
Grant/Research Support: AstraZeneca
Consultant: Bayer
Stock Shareholders: Natera
Shannon Baxter, PhD
Has no relevant financial relationships
Susana Campos, MD, MPH
Consultant: Esai, GlaxoSmithKline, Merck, Pfizer, Immunogen
Michael E. Carney, MD, FACOG
Has no relevant financial relationships
Darlena Chadwick, MBA, MSN, FACHE
Has no relevant financial relationships
Cecilia Choi, MD
Has no relevant financial relationships
Amy L. Cummings, MD, PhD
Consultant: AstraZeneca, Bristol Myers Squibb, Oncohost, Tempus
Don S. Dizon, MD, FACP, FASCO
Grant/Research Support: Bristol Myers Squibb
Consultant: Puma,
Other: Data Safety Monitoring Board: Astra Zeneca, Data Safety Monitoring Board & Change
Management: Clovis
Stock Shareholders: Midi, Doximity
Jami Fukui, MD
Has no relevant financial relationships
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Grant/Research Support: BMS, Pharmacosmos
Nitin Jain, MD
Grant/Research Support: Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC
Therapeutics, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Kite/Gilead,
Mingsight Pharmaceuticals, Takeda, Medisix, Loxo Oncology, Novalgen, Dialectic Therapeutics, Newave
Pharmaceutical Inc., Novartis, Carna Biosciences, Sana Biotechnology, Kisoji Biotechnology
Consultant: Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, BMS, Adaptive Biotechnologies,
Kite/Gilead, Precision Biosciences, Beigene, Cellectis, MEI Pharma, Ipsen, CareDX, MingSight
Pharmaceuticals, Autolus, Novalgen
Robert Kim, MD
Has no relevant financial relationships
Kami J. Maddocks, MD
Consultant: Abbvie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company,
Genetech, Genmab, Incyte, Janssen, Kite, MorphoSys
Midhun Malla, MD, MS
Consultant: Exegesis, Ipsen, Natera
Tom Martin, MD
Grant/Research Support: Sanofi, Janssen, Amgen, BMS
Consultant: GSK, Roche/Pfizer
Shane Y. Morita, MD, MBA, PhD, FACS, FSSO
Has no relevant financial relationships
Misako Nagasaka, MD, PhD
Grant/Research Support: AstraZeneca, Daiichi Sankyo, Lilly, Janssen, BMS/Mirati,
AnHeart/Nuvation, Nuvalent, JintsBIO, D3Bio, Boehringer Ingelheim, Merus
Consultant: Caris Life Sciences
Speakers’ Bureau: Janssen, Pfizer, Takeda, Blueprint Medicine
Stock Shareholders: MBrace Therapeutics
Jorge J. Nieva, MD
Grant/Research Support: Genentech, Merck
Consultant: Aadi Biosciences, Affyimmune, ANP Technologies, Astra Zeneca, BioAtla, G1 Therapeutics,
Genentech, Kalivir Mindmed, Naveris, Sanofi
Stock Shareholders: Cansera, Epic Sciences, Indee Bio, Quantgene, Amgen, Johnson & Johnson, Novartis
Joyce O’Shaughnessy, MD
Has no relevant financial relationships
Alexander B. Olawaiye, MD
Has no relevant financial relationships
Chandler H. Park, MD, MSc, FACP
Grant/Research Support: AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Gilead Sciences, Janssen,
Merck, Pfizer/Roche
Consultant: Aveo, AstraZeneca, Bristol-Myers Squibb, Caris, Exelixis, Eisai, Gilead Sciences, Janssen,
Pfizer, Merck
Speakers’ Bureau: Eisai, Gilead Sciences, Pfizer, AstraZeneca, Merck, Janssen
Mark Pegram, MD
Consultant: Roche/Genentech, Stemline, AstraZeneca/Daiichi Sankyo
Luis E. Raez, MD, FACP, FASCO
Grant/Research Support: AstraZeneca, Pfizer, Velos, Merck, TG Therapeutics, BMS, Natera, Guardant
Health, Genentech, Onc4, Anheart, Arcus Biosciences
Consultant: Bayer, AstraZeneca, Pfizer, Merck, Novartis
Merrick I. Ross, MD
Consultant: Merck – US Global Advisory Board Member
Hope S. Rugo, MD, FASCO
Grant/Research Support: AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc.,
Gilead Sciences, Inc., Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Stemline
Therapeutics, OBI Pharma, Ambryx
Consultant: Chugai, Puma, Sanofi, Napo, Mylan
Stuart Tsuji, MD, PhD
Has no relevant financial relationships
Naoto T. Ueno, MD, PhD, FACP
Grant/Research Support: AnHeart Therapeutics Inc., Eisai Co., Ltd., Gilead Sciences, Inc., Phoenix
Molecular Designs, Daiichi Sankyo, Inc., Puma Biotechnology, Inc., Merck & Co., Oncolys BioPharma Inc.,
OBI Pharma Inc., ChemDiv, Inc., Tolero Pharmaceuticals, Inc., and VITRAC Therapeutics, LLC All have
ended
Consultant: AstraZeneca Pharmaceuticals LP (USA and UK), Bayer AG (ended), Bristol Myers Squibb
Company, Carna Biosciences, Inc., CytoDyn Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly,
Genentech, Inc. (ended), Genomic Health, Inc. (ended), Gilead Sciences, Inc.(ended), Lavender Health
(ended), OncoCyte Corporation (ended), Pear Bio, Peptilogics, Inc.(ended), Pfizer Inc.(ended), Phoenix
Molecular Designs, Preferred Medicine (ended), Carisma Therapeutics Inc.(ended), Sysmex Corporation
(ended), Takeda Pharmaceutical Company Limited (Japan)(ended), and Unitech Medical, Inc.(ended)
Speakers’ Bureau: AstraZeneca Pharmaceuticals LP (ended), Chugai Roche, Inc.(ended), Daiichi Sankyo
Co., Ltd.(ended), Kyowa Kirin Co., Ltd.(ended), Pfizer Inc.(ended), Eli Lilly (ended).
Stock Shareholders: Pear Bio, Phoenix Molecular Designs
Vicente Valero, MD, FACP
Consultant: Novartis, AstraZeneca, Roche
Julie M. Vose, MD, MBA
Grant/Research Support: GenMab/Abbvie, Ipsen, Loxo
Consultant: GenMab/Abbvie
Yousef Zakharia, MD
Consultant: Advisory Board: BMS, EMD Serono, Exelixis, Eisai, Gilead, Janssen, Pfizer, Seagen
Planning Committee – Reported Relevant Financial Disclosure(s)
Sanjiv S. Agarwala, MD, FASCO
Has no relevant financial relationships
Darlena Chadwick, MBA, MSN, FACHE
Has no relevant financial relationships
Don S. Dizon, MD, FACP, FASCO
Grant/Research Support: Bristol Myers Squibb
Consultant: Puma,
Other: Data Safety Monitoring Board: Astra Zeneca, Data Safety Monitoring Board & Change
Management: Clovis
Stock Shareholders: Midi, Doximity
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Grant/Research Support: BMS, Pharmacosmos
Shane Y. Morita, MD, MBA, PhD, FACS, FSSO
Has no relevant financial relationships
Luis E. Raez, MD, FACP, FASCO
Grant/Research Support: AstraZeneca, Pfizer, Velos, Merck, TG Therapeutics, BMS, Natera, Guardant Health, Genentech, Onc4, Anheart, Arcus Biosciences
Consultant: Bayer, AstraZeneca, Pfizer, Merck, Novartis
Hope S. Rugo, MD, FASCO
Grant/Research Support: AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, Ambryx
Consultant: Chugai, Puma, Sanofi, Napo, Mylan
Amy Schippers, PA-C
Has no relevant financial relationships
Teri Valls, CMP, CMM
Has no relevant financial relationships
Julie M. Vose, MD, MBA
Grant/Research Support: GenMab/Abbvie, Ipsen, Loxo
Consultant: GenMab/Abbvie
CME Reviewers – Reported Relevant Financial Disclosure(s)
Sanjiv S. Agarwala, MD, FASCO
Has no relevant financial relationships
Darlena Chadwick, MBA, MSN, FACHE
Has no relevant financial relationships
Lynne Davidson
Has no relevant financial relationships
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Grant/Research Support: BMS, Pharmacosmos
Amy Schippers, PA-C
Has no relevant financial relationships
Teri Valls, CMP, CMM
Has no relevant financial relationships
All of the relevant financial relationships listed for these individuals have been mitigated.
SPEAKERS WILL DIRECTLY DISCLOSETHE USE OF PRODUCTS FOR WHICH ARE NOT LABELED (E.G., OFF LABEL USE) OR IF THE PRODUCT IS STILL INVESTIGATIONAL. EACH SPEAKER HAS BEEN REQUESTED TO KEEP THEIR PRESENTATION UNBIASED AND GENERIC WHEN APPLICABLE
Planning Committee – Relevant Financial Disclosure(s)
Sanjiv S. Agarwala, MD, FASCO
Has no relevant financial relationships
Darlena Chadwick, MBA, MSN, FACHE
Has no relevant financial relationships
Don S. Dizon, MD, FACP, FASCO
Grant/Research Support: Bristol Myers Squibb
Consultant: Puma,
Other: Data Safety Monitoring Board: Astra Zeneca, Data Safety Monitoring Board & Change
Management: Clovis
Stock Shareholders: Midi, Doximity
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Grant/Research Support: BMS, Pharmacosmos
Shane Y. Morita, MD, MBA, PhD, FACS, FSSO
Has no relevant financial relationships
Luis E. Raez, MD, FACP, FASCO
Grant/Research Support: AstraZeneca, Pfizer, Velos, Merck, TG Therapeutics, BMS, Natera, Guardant
Health, Genentech, Onc4, Anheart, Arcus Biosciences
Consultant: Bayer, AstraZeneca, Pfizer, Merck, Novartis
Hope S. Rugo, MD, FASCO
Grant/Research Support: AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc.,
Gilead Sciences, Inc., Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Stemline
Therapeutics, OBI Pharma, Ambryx
Consultant: Chugai, Puma, Sanofi, Napo, Mylan
Amy Schippers, PA-C
Has no relevant financial relationships
Teri Valls, CMP, CMM
Has no relevant financial relationships
Julie M. Vose, MD, MBA
Grant/Research Support: GenMab/Abbvie, Ipsen, Loxo
Consultant: GenMab/Abbvie
CME Reviewers – Relevant Financial Disclosure(s)
Sanjiv S. Agarwala, MD, FASCO
Has no relevant financial relationships
Darlena Chadwick, MBA, MSN, FACHE
Has no relevant financial relationships
Lynne Davidson
Has no relevant financial relationships
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Grant/Research Support: BMS, Pharmacosmos
Amy Schippers, PA-C
Has no relevant financial relationships
Teri Valls, CMP, CMM
Has no relevant financial relationships
All of the relevant financial relationships listed for these individuals have been mitigated.
SPEAKERS WILL DIRECTLY DISCLOSE THE USE OF PRODUCTS FOR WHICH ARE NOT LABELED (E.G., OFF
LABEL USE) OR IF THE PRODUCT IS STILL INVESTIGATIONAL. EACH SPEAKER HAS BEEN REQUESTED TO
KEEP THEIR PRESENTATION UNBIASED AND GENERIC WHEN APPLICABLE.